 |
|
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(3):515-538. Published online 2024 May 10 DOI: https://doi.org/10.3350/cmh.2024.0107
|
|
Citations to this article as recorded by
 Macrophage ATG16L1 promotes liver regeneration after partial hepatectomy
Xinyu Zhan, Yan Bai, Qing Zhu, Yiyun Gao, Fan Li, Qingfa Bu, Zeyu Zhu, Zhuqing Rao, Haoming Zhou
JHEP Reports.2025; 7(5): 101330. CrossRef Unveiling the crossroads of STING signaling pathway and metabolic reprogramming: the multifaceted role of the STING in the TME and new prospects in cancer therapies
Siwei Wang, Lu Qin, Furong Liu, Zhanguo Zhang
Cell Communication and Signaling.2025;[Epub] CrossRef ATG16L1 restrains macrophage NLRP3 activation and alveolar epithelial cell injury during septic lung injury
Yan Bai, Xinyu Zhan, Qing Zhu, Xingyue Ji, Yingying Lu, Yiyun Gao, Fei Li, Zhu Guan, Haoming Zhou, Zhuqing Rao
Clinical and Translational Medicine.2025;[Epub] CrossRef Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Junjie Yu
Clinical and Molecular Hepatology.2024; 30(4): 721. CrossRef Correspondence to editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
Clinical and Molecular Hepatology.2024; 30(4): 1026. CrossRef
|